…
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -20.07M | -27.56M | -57.54M | -28.03M | -43.70M |
| Net income | 41.35M | -27.31M | -56.08M | -27.26M | -40.05M |
| Selling general administrative | 60.88M | 81.71M | 95.17M | 62.51M | 30.14M |
| Selling and marketing expenses | - | 7.95M | 10.44M | 7.75M | 2.79M |
| Gross profit | 41.13M | 58.92M | 42.12M | 22.27M | 10.52M |
| Reconciled depreciation | 8.19M | 5.96M | 7.11M | 5.72M | 0.60M |
| Ebit | -12.61M | -27.56M | -57.54M | -28.03M | -43.70M |
| Ebitda | -5.71M | -21.60M | -50.43M | -22.31M | -43.10M |
| Depreciation and amortization | 6.90M | 5.96M | 7.11M | 5.72M | 0.60M |
| Operating income | -22.35M | -33.93M | -68.12M | -53.53M | -24.09M |
| Other operating expenses | 219.49M | 282.62M | 293.30M | 199.65M | 74.62M |
| Tax provision | 0.00M | -0.26M | -1.47M | -0.77M | -3.64M |
| Interest income | 4.24M | 7.21M | 8.44M | 3.43M | 0.46M |
| Net interest income | 4.24M | 7.21M | 8.44M | 3.43M | 0.46M |
| Income tax expense | -61.41M | -0.26M | -1.47M | -0.77M | -3.64M |
| Total revenue | 197.14M | 248.69M | 225.18M | 146.12M | 50.53M |
| Total operating expenses | 63.48M | 92.84M | 110.24M | 75.80M | 34.61M |
| Cost of revenue | 156.01M | 189.77M | 183.06M | 123.84M | 40.01M |
| Total other income expense net | 2.29M | 6.36M | 10.57M | 25.50M | -19.60M |
| Net income from continuing ops | -20.07M | -27.31M | -56.08M | -27.26M | -40.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 325.47M | 256.68M | 294.94M | 325.02M | 335.88M |
| Intangible assets | 47.50M | 13.65M | 20.52M | 46.37M | 24.42M |
| Other current assets | 25.00M | 12.02M | 19.12M | 15.17M | 6.88M |
| Total liab | 46.40M | 34.74M | 60.64M | 50.54M | 44.51M |
| Total stockholder equity | 279.07M | 221.94M | 234.30M | 274.49M | 291.37M |
| Other current liab | 19.14M | 12.77M | 23.86M | 6.71M | 5.98M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -145.55M | -186.90M | -159.75M | -103.68M | -76.42M |
| Good will | 88.21M | 41.05M | 40.37M | 39.45M | 13.33M |
| Cash | 30.97M | 18.38M | 27.87M | 41.34M | 2.60M |
| Total current liabilities | 19.79M | 22.73M | 35.49M | 26.61M | 12.78M |
| Current deferred revenue | - | 6.66M | 6.84M | 6.71M | 5.98M |
| Net debt | -27.66M | -9.06M | -3.35M | -23.01M | -1.88M |
| Short term debt | 0.65M | 3.30M | 4.79M | 3.36M | 0.44M |
| Short long term debt total | 3.31M | 9.32M | 24.52M | 18.33M | 0.72M |
| Other stockholder equity | 424.62M | 407.08M | 390.08M | 375.87M | 368.68M |
| Total current assets | 126.19M | 160.74M | 206.26M | 218.13M | 294.94M |
| Long term investments | - | - | - | 0.39M | 0.20M |
| Short term investments | 30.26M | 108.76M | 138.26M | 150.74M | 279.37M |
| Net receivables | 39.96M | 21.59M | 21.00M | 10.88M | 5.55M |
| Inventory | - | - | - | 1.13M | 0.55M |
| Accounts payable | 19.14M | - | - | 16.54M | 6.37M |
| Accumulated other comprehensive income | - | 1.75M | 3.96M | 2.29M | -0.90M |
| Non currrent assets other | 24.02M | 1.44M | 1.40M | 1.36M | 0.23M |
| Non current assets total | 199.28M | 95.93M | 88.68M | 106.90M | 40.94M |
| Capital lease obligations | 3.31M | 9.32M | 24.52M | 18.33M | 0.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 150.10M | -1.02M | 17.09M | 79.34M | -321.34M |
| Total cashflows from investing activities | 69.75M | -1.02M | 17.09M | 79.34M | -321.34M |
| Net borrowings | - | - | - | 0.00M | -1.17M |
| Total cash from financing activities | -8.91M | -5.76M | -0.08M | -1.08M | 332.26M |
| Net income | 41.35M | -27.31M | -56.08M | -27.26M | -40.05M |
| Change in cash | 11.59M | -9.37M | -15.40M | 36.84M | -4.69M |
| Begin period cash flow | 19.65M | 29.02M | 44.42M | 7.58M | 12.28M |
| End period cash flow | 31.23M | 19.65M | 29.02M | 44.42M | 7.58M |
| Total cash from operating activities | -48.91M | -2.52M | -32.35M | -37.13M | -15.62M |
| Issuance of capital stock | - | - | - | 0.00M | 119.63M |
| Depreciation | 8.19M | 5.96M | 7.11M | 5.72M | 0.60M |
| Other cashflows from investing activities | -1.42M | -2.11M | 0.14M | - | -0.50M |
| Change to account receivables | -12.03M | -1.00M | -10.25M | -5.35M | -0.41M |
| Sale purchase of stock | 0.00M | -0.24M | 0.00M | - | - |
| Other cashflows from financing activities | -9.11M | -5.51M | -0.15M | -1.17M | 333.28M |
| Capital expenditures | 11.01M | 32.99M | 2.11M | 0.73M | 0.30M |
| Change in working capital | -9.08M | -3.01M | -6.74M | -0.02M | -2.20M |
| Stock based compensation | 17.83M | 19.89M | 12.50M | 8.28M | 9.62M |
| Other non cash items | -107.63M | 2.20M | 12.32M | -23.08M | 20.06M |
| Free cash flow | -59.92M | -35.51M | -34.46M | -37.86M | -15.91M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SRTA Strata Critical Medical, Inc. |
0.30 5.70% |
5.56 | - | 138.89 | 1.83 | 1.70 | 1.78 | -9.95 |
| HCA HCA Healthcare, Inc. |
-12.49 2.46% |
494.99 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-3.13 1.09% |
283.33 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.06 0.42% |
14.62 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% |
5.28 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
666 Third Avenue, New York, NY, United States, 10017
(917) 781-3190
327
| Name | Title | Year Born |
|---|---|---|
| Ms. Melissa M. Tomkiel J.D. | Co- CEO, General Counsel, Corporate Secretary & Director | 1981 |
| Mr. William A. Heyburn | Co-CEO, CFO & Director | 1989 |
| Mr. Amir M. Cohen | Chief Accounting & Integration Officer | 1977 |
| Mr. Scott M. Wunsch | Chief Executive Officer of Logistics Services | 1977 |
| Mr. Mathew Schneider C.F.A. | CFO of Clinical Services & VP of Finance and Investor Relations | NA |
| Mr. Keith Trepanier | Chief of Safety | NA |
| Mr. Louis R. Verdetto | Chief Executive Officer of Clinical Services | 1984 |
| Dr. Scott Silvestry | Chief Medical Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.